Meet the new E2B(R3) ICSR reporting requirements for Republic of Korea with WHODrug Link Korea. From 2021, local Korean drug code identifiers are required to be submitted when reporting domestic Korean adverse drug reaction (ADR) cases. Developed in response to the Republic of Korea’s new regulations, WHODrug Link Korea effectively converts codes from WHODrug Global to local Korean codes, making the regulatory submission process easier and more efficient for WHODrug users.
This new addition to the WHODrug portfolio will be officially launched on 1 March 2021. Until then, an evaluation file is available to all interested WHODrug users upon request. Review a sample of the mapped data to provide feedback on the format and structure of the files with the evaluation file. For more information, please contact us at WHODrug@who-umc.org.
UMC has also reached out to vendors within the WHODrug Vendor Programme and provided them with an opportunity to share their implementation plans for WHODrug Link Korea. Read more about it here.